Clemence Delcourt
Chief Investment Officer at Danone Manifesto Ventures, Inc.
Profile
Clemence is the Managing Director and Chief Investment Officer at Danone Manifesto Ventures.
She brings a wealth of knowledge as both a financial leader and operator to the team.
Clemence’s expertise leading deals combined with her strategic business partner roles as CFO provides a well-rounded and knowledgeable perspective to DMV’s portfolio partners.
Prior to joining Danone Manifesto Ventures, Clemence was the SVP Business Planning and Performance Management leader for Danone North America.
Over her 13-year career at Danone, she has led various finance functions across global Danone business units as well as led deals in Corporate Development.
Prior to joining Danone, Clemence started her career in M&A at Lazard, both in Paris and NY.
Clemence is a graduate of HEC Paris, having majored in business entrepreneurship.
Clemence Delcourt active positions
Companies | Position | Start |
---|---|---|
Danone Manifesto Ventures, Inc.
Danone Manifesto Ventures, Inc. Investment ManagersFinance Danone Manifesto Ventures Inc (Danone Manifesto Ventures) is a venture capital subsidiary of Danone SA founded in 2016. The firm is headquartered in New York. | Chief Investment Officer | 2021-08-31 |
Former positions of Clemence Delcourt
Companies | Position | End |
---|---|---|
Danone Medical Nutrition North America, Inc.
Danone Medical Nutrition North America, Inc. Specialty StoresRetail Trade In 2008, Danone recorded an organic growth rate of 8.4% - practical proof that its business growth model truly works. With its operating margin increasing for the 14th year running, the group further strengthened its global standing: world no. 1 in fresh dairy products, world no. 2 in bottled waters, world no. 2 in baby nutrition and European no. 1 in medical nutrition. The group's performance is the result of a balanced strategy that builds on international expansion, a growing commitment to innovation, and strengthening health-oriented brands. In order to live up to its ambitions, Danone invests heavily in Research & Development - €208 million in 2008. One hundred percent of projects currently in the pipeline focus on health and nutrition. Three centuries after the benefits of Evian mineral water were discovered, over a century after Blédine was first marketed, and nearly a century after the first Danone yoghurt was retailed in a pharmacy, health innovation remains more than ever a driver of the group's business growth. 2008 confirmed that the previous year's acquisition of the Dutch group Numico was strategically sound. With this move, Danone incorporated into its strategy two profitable, fast-growing health-oriented business lines: medical nutrition and baby nutrition. They naturally round off the group's brand portfolio and are perfectly aligned with its mission to bring health through food to as many people as possible. Today Danone is the only food group to focus totally on health. | Private Equity Investor | 2021-10-31 |
Danone Canada | Director of Finance/CFO | 2014-06-30 |
DANONE | Director/Board Member | 2011-05-31 |
Training of Clemence Delcourt
École des Hautes Études Commerciales de Paris | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
DANONE | Consumer Non-Durables |
Private companies | 3 |
---|---|
Danone Medical Nutrition North America, Inc.
Danone Medical Nutrition North America, Inc. Specialty StoresRetail Trade In 2008, Danone recorded an organic growth rate of 8.4% - practical proof that its business growth model truly works. With its operating margin increasing for the 14th year running, the group further strengthened its global standing: world no. 1 in fresh dairy products, world no. 2 in bottled waters, world no. 2 in baby nutrition and European no. 1 in medical nutrition. The group's performance is the result of a balanced strategy that builds on international expansion, a growing commitment to innovation, and strengthening health-oriented brands. In order to live up to its ambitions, Danone invests heavily in Research & Development - €208 million in 2008. One hundred percent of projects currently in the pipeline focus on health and nutrition. Three centuries after the benefits of Evian mineral water were discovered, over a century after Blédine was first marketed, and nearly a century after the first Danone yoghurt was retailed in a pharmacy, health innovation remains more than ever a driver of the group's business growth. 2008 confirmed that the previous year's acquisition of the Dutch group Numico was strategically sound. With this move, Danone incorporated into its strategy two profitable, fast-growing health-oriented business lines: medical nutrition and baby nutrition. They naturally round off the group's brand portfolio and are perfectly aligned with its mission to bring health through food to as many people as possible. Today Danone is the only food group to focus totally on health. | Retail Trade |
Danone Manifesto Ventures, Inc.
Danone Manifesto Ventures, Inc. Investment ManagersFinance Danone Manifesto Ventures Inc (Danone Manifesto Ventures) is a venture capital subsidiary of Danone SA founded in 2016. The firm is headquartered in New York. | Finance |
Danone Canada |
- Stock Market
- Insiders
- Clemence Delcourt